5.3 Non-Pharmacological Options & Evidence-Based OTC Choices

Non-drug care is not a consolation prize

Patients often expect a product. Competent pharmacists still lead with what works, including measures that do not come in a box. Non-pharmacological advice can be first-line, adjunctive, or the entire plan when medicines add more risk than benefit. On exam items, the best answer frequently combines education + selective OTC + clear safety-net, not the most expensive multi-ingredient pack on the shelf.

Use plain Australian English, check understanding, and tailor advice to age, culture, health literacy, and living situation. Written consumer medicines information and APF counselling structures help standardise key points, but spoken counselling should still be personalised.

High-yield non-pharmacological strategies

Hydration and supportive care in acute illness

For gastroenteritis, feverish viral illness, and many respiratory infections, fluid intake, rest, and nutrition as tolerated reduce complications. Oral rehydration solutions are preferable to high-sugar soft drinks or undiluted fruit juice when dehydration risk is real. Advise small frequent sips if nausea is present. Explain red flags for dehydration that trigger medical review (see Section 5.1).

Musculoskeletal pain and physiotherapy referral concepts

For simple strains and non-specific back pain without red flags (no trauma with possible fracture, no saddle anaesthesia, no progressive neurology, no infection/cancer concerns), encourage early appropriate activity, heat/cold as preferred, short-term analgesia if needed, and consideration of physiotherapy or exercise-based care rather than prolonged bed rest. Pharmacists do not replace physiotherapists, but they can explain why movement and professional rehab advice may outperform escalating medicine stacks.

Smoking cessation support

Smoking cessation is among the highest-value interventions in primary care. Offer brief advice using a simple structure: ask about use, advise quitting, assess readiness, assist with a plan, arrange follow-up. Evidence-based aids include behavioural support and, where appropriate, nicotine replacement therapy (patch, gum, lozenge, inhalator, mouth spray — often combination NRT for dependent smokers) or referral for prescription medicines when indicated. Emphasise that cutting down without a plan is less effective than a quit date plus support, though any reduction in exposure helps some risk pathways. Link to Quitline and local programs where available.

Lifestyle measures for GORD / reflux

Before or alongside short-course acid suppression for typical symptoms:

• Weight reduction if overweight
• Elevate the head of the bed for night symptoms
• Avoid late large meals; trial reduction of known personal triggers (alcohol, caffeine, chocolate, fatty meals, mint — individualise rather than moralise)
• Review medicines that worsen reflux (for example some calcium channel blockers, nitrates, NSAIDs) with the care team when relevant
• Avoid tight clothing around the abdomen if symptomatic

Refer when red flags exist: dysphagia, odynophagia, GI bleeding signs, progressive unintentional weight loss, persistent vomiting, iron-deficiency anaemia, or new onset in older adults without prior diagnosis.

Constipation — start with the basics

First-line non-drug measures include adequate fluid, dietary fibre (increased gradually), and physical activity. Address medicines that constipate (opioids, some anticholinergics, iron, verapamil, ondansetron, and others). If laxatives are needed, match class to situation (bulk-forming when fluid intake is adequate; osmotic agents commonly used; stimulants short-term or as part of opioid regimens with a plan). Opioid-induced constipation usually needs a proactive laxative plan, not fibre alone.

Other practical non-drug examples

• Insomnia: sleep timing, caffeine/alcohol reduction, screen hygiene; caution long-term sedating antihistamines.
• Allergic rhinitis: allergen reduction measures; saline irrigation; consider intranasal corticosteroid technique education when therapy is appropriate.
• Dermatitis: soap-free washes, emollients liberally, trigger avoidance; steroid potency/duration counselling when used.
• Infant colic / mild viral symptoms: parental support and safe settling advice; avoid harmful traditional remedies.

Matching OTC medicines to evidence and risk

Paracetamol versus NSAIDs

Both are useful; they are not identical.

Paracetamol

• Often suitable first-line for mild–moderate pain and fever when used within maximum daily dose limits
• Watch combination products that hide extra paracetamol
• Use caution in significant liver disease and with chronic heavy alcohol use; still often usable with careful dosing advice, guided by clinical references

NSAIDs (for example ibuprofen, naproxen, diclofenac where non-prescription strengths/forms apply)

• Anti-inflammatory benefit for some musculoskeletal and dental pains
• Risks: gastrointestinal ulceration/bleeding, renal impairment (especially if dehydrated, elderly, on ACE inhibitor/ARB + diuretic “triple whammy”), cardiovascular risk with some agents/durations, fluid retention, asthma exacerbation in NSAID-sensitive patients, and pregnancy concerns especially later pregnancy
• Prefer shortest duration and lowest effective dose; take with food as counselled; avoid stacking multiple NSAIDs

Exam pattern: an elderly patient on an ACE inhibitor and diuretic with reduced oral intake who wants ibuprofen for a sprain is a renal risk vignette — favour non-drug measures ± paracetamol if appropriate, and medical review if needed.

Combination cold and flu products

Multi-ingredient products can help adherence when each ingredient is indicated, but they increase the chance of duplication (paracetamol) and unnecessary exposure to decongestants, sedating antihistamines, or cough suppressants without evidence of need. Prefer targeted therapy: treat the dominant symptom with the simplest effective product.

Proton pump inhibitors — short courses for self-care

Non-prescription PPIs may be appropriate for frequent typical heartburn in eligible adults for a limited course (follow current product and professional guidance), after considering lifestyle measures and excluding red flags. Key counselling points:

• Not for immediate relief of occasional heartburn (antacids/alginates act faster)
• May take days for full effect
• Do not continue indefinitely without review — prolonged PPI use has been associated with various risks and can mask serious disease
• Reassess if symptoms recur rapidly, worsen, or atypical features appear
• Interactions and hypomagnesaemia/other long-term issues matter more with extended use and comorbidities

If breakthrough symptoms are severe or alarm features exist, refer rather than escalating OTC acid suppression repeatedly.

Decongestant cautions

Oral sympathomimetic decongestants (for example pseudoephedrine; phenylephrine products where marketed) may relieve nasal congestion for some adults but carry cautions:

• Hypertension and cardiovascular disease
• Hyperthyroidism
• Prostatic hypertrophy / urinary retention risk contexts
• MAOI interactions and other significant drug interactions
• Insomnia, agitation, tachycardia
• Diversion and real-time recording obligations for pseudoephedrine-containing products

Topical nasal decongestants can cause rebound congestion (rhinitis medicamentosa) if used beyond a few days. Saline sprays/irrigation and treating underlying allergic rhinitis appropriately are often safer foundations. For many viral colds, non-drug measures and time are enough.

Cough preparations

Evidence for many cough mixtures is limited. Honey (in children old enough — not in infants under 12 months because of botulism risk) and simple demulcents may help some patients. Codeine-containing cough products are not an OTC solution in modern Australian scheduling practice for routine colds; focus on cause, asthma/COPD review if cough is recurrent, and red-flag chronic cough referral.

Pregnancy and lactation — conceptual use of AMH safety information

Pregnancy and breastfeeding change the benefit–harm equation. Core principles:

1. Confirm pregnancy/lactation status early in the assessment for women of childbearing potential when relevant.
2. Prefer non-pharmacological options first when effective.
3. Choose medicines with the best-established safety data for the gestation stage or for lactation, at the lowest effective dose for the shortest time.
4. Use AMH (and product information) for pregnancy categories/summaries and lactation comments as your restricted open-book authority during the exam — learn how to interpret them rather than memorising every agent.
5. Treat “natural” products with the same caution; herbal is not automatically safe.
6. Refer when symptoms are severe, atypical, or potentially obstetric (abdominal pain, bleeding, severe headache with visual change, suspected pre-eclampsia features, dehydration from hyperemesis, febrile illness with concerning features).

Conceptual AMH pregnancy classification thinking (categories can change; always verify current AMH):

• Categories communicate quality of data and risk signals, not a simple green/red shopping label.
• A medicine in a more favourable category is not automatically indicated; it still needs a clinical reason.
• A medicine with concerning pregnancy data may still be essential under specialist care for serious disease — that is a prescriber-level decision, not an OTC upsell.

Practical OTC examples often tested:

• Nausea in pregnancy: non-drug measures first; some pharmacies supply recognised options under protocol/professional guidance — know when to refer for hyperemesis.
• Pain/fever: paracetamol has commonly been preferred when an antipyretic/analgesic is needed; NSAIDs are particularly problematic in later pregnancy and need caution generally.
• Constipation: fluids, fibre, exercise; appropriate laxatives if needed with reference checks.
• Reflux: lifestyle first; antacids/alginates often used; acid suppression choices need reference-based selection and medical involvement for persistent symptoms.
• Lactation: consider infant age, milk supply concerns, and relative infant dose concepts at a high level; prefer medicines with good lactation data and counsel on timing if relevant.

Bringing evidence and values together

Evidence-based OTC choice is not only “what the Cochrane review says.” It is the intersection of:

• Best available evidence for benefit
• Patient-specific harms and comorbidities
• Medicine schedule and legal supply rules
• Patient preferences and health literacy
• Cost and adherence practicality
• Clear review points and referral thresholds

A rigorous pharmacist might refuse a decongestant, recommend saline and steam (if safe for the patient), suggest paracetamol for fever within dose limits, discuss expected cold duration, offer smoking cessation help if relevant, and provide specific return precautions — that package is often better care than a three-agent night/day cold box.

Study link to open-book resources

When practising questions, force yourself to name one non-drug step before you name a product. Then justify the product with indication + risk screen + duration. If pregnancy/lactation appears, mentally open AMH first. If reflux or analgesia appears, actively compare lifestyle, paracetamol, NSAID risks, and PPI course length. That habit mirrors both Standard 3.2.2 and real Australian community practice.